Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Terri Katz

Geriatric Medicine Fort Lee, NJ Medical Doctor

NPI 1588764005 CMS profile 298522

1530 Palisade Ave, Fort Lee, NJ 07024

Open in the dashboard

General payments

$1,712

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terri Katz of Fort Lee, NJ is reported in the CMS Open Payments database as having received $1,712 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $526 23
2024 General $643 36
2023 General $529 31
2019 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terri Katz
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Terri Katz were reported at $526. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Terri Katz Geriatric Medicine median Middle half National median
2019 $15 $122 $40–$435 $163
2020 $0 $98 $25–$349 $114
2021 $0 $125 $34–$441 $132
2022 $0 $124 $36–$408 $149
2023 $529 $121 $41–$383 $160
2024 $643 $134 $41–$435 $164
2025 $526 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $403 18 payments
  2. Otsuka America Pharmaceutical, Inc. $183 10 payments
  3. Lilly USA, LLC $168 9 payments
  4. Novo Nordisk Inc $129 7 payments
  5. Madrigal Pharmaceuticals $122 5 payments
  6. Lundbeck LLC $104 6 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $74 4 payments
  8. Pfizer Inc. $65 4 payments
  9. Sanofi-Aventis U.S. LLC $50 3 payments
  10. AstraZeneca Pharmaceuticals LP $49 3 payments
  11. Other $364 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,697 90 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $183 10 payments
  2. SHINGRIX $155 9 payments
  3. TRELEGY ELLIPTA $126 8 payments
  4. AREXVY $122 1 payment
  5. REXULTI Psychiatry $104 6 payments
  6. REZDIFFRA $82 4 payments
  7. RYBELSUS $70 4 payments
  8. Ozempic $67 4 payments
  9. MOUNJARO $58 3 payments
  10. ENTYVIO $56 3 payments
  11. Other $1,091 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 145 drugs

Part D claims

8,043

Median for Geriatric Medicine: 2,306

Drug cost

$512,339

Median for Geriatric Medicine: $150,713

Branded share of claims

16.6%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 22 $116,137
Eliquis Apixaban Brand 220 $103,295
Xarelto Rivaroxaban Brand 43 $28,953
Perseris Risperidone Brand 12 $27,601
Jardiance Empagliflozin Brand 48 $23,086
Myrbetriq Mirabegron Brand 18 $21,187
Januvia Sitagliptin Phosphate Brand 23 $14,651
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $12,676
Farxiga Dapagliflozin Propanediol Brand 22 $9,188
Atorvastatin Calcium Generic 564 $7,365

The 10 drugs with the highest cost, of 145 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$146,649

Of which drugs: $9,201

Medicare patients

537

Average age 85

Services billed

1,931

396 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 40%
Depression 39%
Alzheimer's or dementia 37%
Atrial fibrillation 35%
Diabetes 34%
Heart failure 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 23 23 $6,371
Vaccine for influenza for injection into muscle 90662 Office 33 33 $2,700

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $74
  • Lundbeck LLC $35
$110 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $53
$53 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $50
$50 — —
RESMETIROM
  • Madrigal Pharmaceuticals $40
$40 — —
AMYVID
  • Lilly USA, LLC $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record